NCT05133752View on ClinicalTrials.gov

Oral Nemonoxacin in Treating Elderly Patients With CAP

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 11, 2018

Primary Completion Date

March 23, 2020

Study Completion Date

March 23, 2020

Conditions
Community-acquired Pneumonia
Interventions
DRUG

Nemonoxacin

500 mg, oral administration, once daily for 7-10 days.

Trial Locations (1)

Unknown

Tri-Service General Hospital, Taipei

All Listed Sponsors
lead

TaiGen Biotechnology Co., Ltd.

INDUSTRY

NCT05133752 - Oral Nemonoxacin in Treating Elderly Patients With CAP | Biotech Hunter | Biotech Hunter